A B S T R A C T Metabolic properties of the four subclasses of human IgG were investigated by performing 47 turnover studies in individuals with normal IgG serum concentrations, as well as in patients with an increased level of one of the subclasses. Studies in 12 subjects with normal IgG serum concentration showed that the average biologic half-life of Gi, G2, and Ga was 21 days, while that of Gs was only 7.1 days. Fractional catabolic rates of Ga, G2, and G4 were 6.9 to 8% of the intravascular pool per day. Gs, however, had a higher fractional catabolic rate, amounting to 16.8% of the intravascular pool per day. Distribution of the subclasses was such that the intravascular compartment contained 51-54% of the total body pools of Ga, G2, and G4, but 64% of the total body pool of Ga.
INTRODUCTION
Many metabolic features of human IgG have been demonstrated by turnover studies using IgG isolated from normal human serum. IgG, however, is heterogeneous and consists of four distinct species of molecules de- signated IgGa, Ga, G, and G4. All four of these subclasses are present in normal human serum, and in a normal indivdual the relative concentrations are: Ga, 65%; G2, 23%; G, 8%; and Ga, 4% (1) . Previous studies have, therefore, really determined the metabolic properties of a heterogeneous group of proteins.
Molecules of the four subclasses differ from one another in the antigenic and chemical structure of the carboxy terminal three-quarters of their gamma chains. One portion of this region, the Fc-fragment, determines a number of the biologic, nonantibody activities of IgG, including the rate of catabolism (2, 3) . The subclasses differ in their Fc-fragments and therefore might also be expected to differ in metabolic properties. Investigation of characteristics of indivdual subclasses cannot be performed using normal serum IgG, because the molecules in normal serum have very similar charge and size and cannot be completely separated from one another. It is necessary, instead, to use G-myeloma proteins (G-MP) each of which serves as a representative of a subclass and can be obtained free of other subclasses.
Spiegelberg and coworkers (4, 5) have investigated one aspect of the metabolism of human IgG subclasses by comparing the biologic half-life of a number of isolated G-MP's in man and other species. They found that the average biologic half-life of Gi, G2, and Ga were similar, but that the half-life of Ga was shorter than the others.
The purpose of the present study was to gather more information about the metabolism of the IgG subclasses a method of inhibition of immune binding (7) . Monkey or rabbit antisera were absorbed so as to be specific for the heavy chains of IgG, G1, or Gs. Specific antisera were made 14%o in Na2SO4 and the precipitated globulin fractions were coupled to bromacetyl cellulose. These immunoadsorbents quantitatively bind their homologous radiolabeled antigens. The binding is inhibited by unlabeled antigen of the same specificity, and the degree of inhibition is quantitatively proportional to the concentration of the unlabeled antigen. IgA and IgM concentrations were measured by radial immunodiffusion (8) .
Patient selection. 12 patients with a variety of neoplastic diseases were selected because they had relatively normal serum IgG concentrations (Table I) . Ages ranged from 20 to 72 yr; four were male, and eight female. 10 additional patients were selected because their serum contained a myeloma protein, thus permitting metabolic studies in eight individuals with a high G1 serum concentration, one individual with a high G2 serum concentration, and one with a high G3 serum concentration (Table II) . Patients' ages ranged from 33 to 77 yr; three were female, seven male. No patients in either group had signs of significant gastrointestinal or renal protein loss.
Turnover study protocol. All subjects were hospitalized at the National Institutes of Health and studies were not performed during periods of acute illness. The serum concentrations of IgG, G., and G8 remained constant in both the control and myeloma patients during the study periods, and all patients were therefore assumed to be in a steady state concerning IgG metabolism. 5 drops of Lugol's solution were given three times a day during the entire study to prevent uptake of radioactive iodine by the thyroid.
Subj ects received pairs of subclass preparations intravenously, one preparation labeled with 'I, the other with 'I. The dose of radioactivity ranged from 10 to 25 ,uCi.
A 10 min blood sample was drawn for' plasma volume determination. Additional blood samples were collected at 4 hr, 8 with appropriate standards in an automatic gamma ray welltype scintillation counter with a thallium-activated sodium iodide crystal. A pulse height analyzer allowed differentiation of the two isotopes in the samples.
In vivo labeled G.-myeloma protein turnover study. A single intravenous dose of 100 1ACi of guanidoarginine-14C
was given to patient G. B. who had a serum Ga-myeloma protein (Table II) . Plasma samples were obtained daily. The myeloma protein was isolated from each plasma sample, and 5 mg of the protein were completely precipitated with 10% trichloracetic acid. Precipitates were dissolved in 0.5 ml of NCS reagent (Nuclear-Chicago),' 10 ml of a mixture of Liquifluor (New England Nuclear)' and toluene was added, and radioactivity was determined in a liquid scintillation counter (Packard Tri-Carb Model 4322).' The rate of decrease of specific activity of the Ga-myeloma protein reflects the biologic survival of this protein.
Calculation of the metabolic data. Whole body radioactivity was calculated by cumulative subtraction of the radioactivity appearing in the urine. Graphs of change in plasma and whole body radioactivity were constructed on semilogarithmic paper. The biologic half-life (tj) of each labeled protein was determined graphically. The total circulating and total body protein pools, the fraction of the body protein pool remaining intravascular, the fraction of the intravascular pool catabolized each day (fractional catabolic rate or FCR), and the synthetic rate (turnover rate) were determined by a modification of the method of Matthews (9) .
RESULTS
Subjects with normal IgG levels. Turnover data from studies in subjects with normal serum IgG concentrations are summarized in Table I . Five subjects received "3I-G4K and 'I-G1X simultaneously, one was injected 2 Nuclear-Chicago Corporation, Des Plaines, Ill. 'New England Nuclear Corp., Boston, Mass. 'Packard Instrument Co., Downers Grove, Ill. only with 1"I-G1X, four received 'I-G2K and 'I-GsK simultaneously, and two received only 'I-G3X.
The biologic half-life of the Go, Gs, and Go proteins showed considerable variation when studied in different individuals. Average values, however, were similar for all three subclasses (Table I ). The observed half-times of survival of 20.2 to 21.2 days are similar to those previously reported for whole IgG (23 +4 days) (10) . The survival of both Ga proteins, however, was short, with a mean of 7.1 ±0.7 days (Table I) .
The fraction of the intravascular pool catabolized per day (FCR) of the four subclasses is shown in Table I . Rates for Gi, G2, and G. were between 0.05 and 0.10 of the intravascular pool per day, values which are similar to the FCR of whole IgG (0.067 ±0.015). The fractional catabolic rates of the Gs proteins were considerably higher and ranged from 0.159 to 0.175 of the intravascular pool per day.
It was necessary to determine whether the short survival and high fractional catabolic rate of Gs was due to damage of this labile molecule during isolation and radiolabeling, or whether this rate was indeed a metabolic property of native Ga. To accomplish this, an in vivo labeling procedure was utilized so that it was not necessary to isolate and label the Ga-myeloma protein prior to its metabolism in vivo. Patient G.B., whose serum contained a Gs-myeloma protein (Table II) , was given a single intravenous dose of 100 .Ci of guanidoarginine-"C. On each of the 10 following days (except day 9) plasma samples were obtained, myeloma protein was isolated, and specific activity determined (see Methods). "C was rapidly incorporated into the myeloma protein, such that the specific activity was high 24 hr (Table I) . Using these serum concentrations, total circulating, and total body pools for IgG, Gi, and G3 were calculated (Table I ). The distribution of Gs into the intravascular compartment was relatively high, and amounted to an average of 64% of the total body pool. By comparison, only 51, 53, and 54% of the total body pools of Ga, Ga, and G4 were located in the intravascular compartments.
Synthetic rates for G1 and Gs in the patient group with normal IgG concentrations were calculated and compared with the synthetic rate of IgG, which has previously been reported as 34 ±11 mg/kg per day (10) .
Although there was a considerable range in the individual values for Ga synthesis, the average rate was 25 ±14 mg/kg per day, which is 70% that of IgG. By contrast, the average G3 synthetic rate was 3.4 ±0.7 mg/kg per day, or about 10% of the synthetic rate of IgG.
Myeloma patients. Table II summarizes the turnover data of the myeloma patients. As shown in previous studies (10, 11) , myeloma patients have a higher plasma volume than normal individuals. In the present study, the plasma volume of the myeloma patients averaged 53 ±10 ml/kg, compared to 42 ±4 ml/kg in the control patients. The intravascular compartment contained 59, 56, and 59% of the total body pools of Ga, G2, and G4, and 77% of the total body pool of G3.
The survival of each of the subclasses was significantly shorter in myeloma patients than in controls, and the FCR was approximately twice that of controls. A possible explanation for the shortened survival relates to IgG concentration, in that it has previously been noted that patients with elevated IgG serum concentrations have shortened survival of IgG (10, (12) (13) (14) (15) ; that is, there appears to be an inverse relationship between serum IgG concentration and IgG survival. In the present study, survival times generally were shortest in recipients with the highest IgG levels. Studies in patients with elevated serum levels of Ga, G2, or G showed that survival of all four subclasses were decreased and catabolic rates increased (Figs. 2, 3 IgG of the subclasses other than the myeloma protein, or of the same subclass but of the other light chain type) is usually markedly decreased (Table II) . For example, the average G1X serum concentration in eight patients with myeloma proteins of non-GLX type was 0.7 mg/ml, as compared to an average of 2.8 mg/ml in nonmyeloma patients. The rates of synthesis of nonmyeloma IgG are about 1 SD below the average synthetic rates of control patients. The low levels of "nonmyeloma" IgG are, therefore, due not only to the increased fractional catabolic rate (Tables I and II) but also to reduced synthesis (Fig. 4) . DISCUSSION The biologic half-lives and fractional catabolic rates of the Gi, G2, and G4 subclasses were similar to one another and to the values previously reported for IgG. It is not surprising that the survival of G, and G2 should be similar to that of IgG, since G1 and G2 constitute approximately 90% of the IgG used in previous studies. In the only other reported turnover study of the IgG subclasses, considerably shorter survival times were reported for Gi, G2, and G4 (11.6, 12.4, and 11.3 days respectively) (4). This discrepancy may be due to differences in radiolabeling techniques, since these investigators used the chloramine-T method, and proteins labeled by that procedure may have shortened survival times.
IgG3 was catabolized two to three times more rapidly than the other subclasses. Gs, however, is known to be a labile molecule (16) . It may be fragmented upon serum storage and is very rapidly destroyed by proteolytic enzymes. It was necessary, therefore, to prove that the apparent short survival was not due to molecular degradation occurring during the isolation and radiolabeling of the myeloma protein. This possibility was tested by biosynthetically labeling a G3-myeloma protein, thus avoiding the need to isolate and radiolabel the protein before injecting it for turnover study. In this procedure, isolation of the G3 protein occurs after metabolism has taken place and any damage occurring during isolation does not affect the results. A patient with a G-myeloma protein was chosen for this study, since the low level of G3 in normal serum makes it very difficult to isolate normal serum Gs free of other serum proteins. Results of this study clearly show that the in vivo and in vitro labeled G3 are metabolized similarly ( Fig. 1) In IgG-myeloma patients the concentration of nonmyeloma IgG is usually decreased (20, 21 (Fig. 2) . G proteins showed a similar relationship, although the curve is displaced from that produced by IgG (Fig.  3) . Two G8 metabolic studies were performed in patients with hypogammaglobulinemia. The survival of G3 in these patients was two to three times longer than in recipients with normal IgG concentrations, and seven times longer than in a patient with multiple myeloma and an IgG serum concentration of 30 mg/ml (Fig. 3) .
Murine serum also contains definable IgG subclasses whose metabolic properties have been studied. The results are quite parallel to those found in man. One of the murine subclasses, t2b (YGH) has a shorter survival and higher fractional catabolic rate than the other subclasses (24) . In mouse, as in man, a concentrationcatabolism relationship has been observed; mice with high serum levels of IgG have high fractional catabolic rates, while those with low serum levels have low catabolic rates and long survival (23, 25) .
The mechanism by which IgG is metabolically degraded is unknown. Brambell The concentration-catabolism relationship demonstrated for a majority of the patients in the present study is consistent with this hypothesis and expands it by indicating that there are no subclass specific protective receptor sites. All four subclasses compete for the same receptors. A myeloma protein of any of the subclasses therefore would, by the overwhelming number of its molecules, occupy almost all the protective sites, leaving the molecules of the other subclasses exposed to catabolism at a high rate. The hypothesis must be modified, however, to account for the facts that Gs participates in the concentration-catabolism relationship, but has a much higher catabolic rate. This indicates that although G3 proteins share metabolic pathways with the other subclasses, they also are acted upon by other catabolic mechanisms. The location of catabolic sites and the details of both the catabolic mechanisms proposed by Brambell and the additional ones suggested by these studies are unknown at this time.
